LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)– #Cardiology–The FDA has granted HAYA Therapeutics Fast Track Designation for HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
